---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000520"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:04:44.200111+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta promotes David R. Shook, M.D., to Chief Medical Officer

## Summary
- Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.
- He has extensive cell therapy development experience, including first-in-human trials with CD19 CAR-NK cells.
- Dr. Shook co-developed the membrane-bound IL-15 component of Nkarta’s NK cell platform.
- He continues as a practicing pediatric oncologist and transplant physician.
- Prior Nkarta, he was at St. Jude Children’s Research Hospital in the lab of scientific founder Dario Campana.

## SEC filing metadata
- accession: 0000950170-23-000520
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/0000950170-23-000520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023000520/nktx-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000520
- JSON: https://secwatch.observer/filing/0000950170-23-000520.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.